HHS is requesting changes to prescribing information for testosterone therapy products following a review of new clinical data and scientific evidence, according to a press release from the agency.As Healio previously reported, the FDA convened a panel in December that discussed removing some contraindications for testosterone therapy as well as taking testosterone therapy off the list of controlled substances. In an announcement on June 18, HHS proposed three changes to testosterone therapy labeling.The first of the three changes would remove the limitation of use stating that safety and
